IRB #

STUDY00015953

Title

A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Principal Investigator

Rachel Cook

Study Purpose

The purpose of this study is to test any good and bad effects of the study drug called SY-1425 (tamiboratene) in patients with acute myeloid leukemia (AML) who have a certain biomarker in their blood (a blood test may indicate the drug target is present in your type of AML).

Medical Condition(s)

Acute Myeloid Leukemia (AML)

Eligibility Criteria

-At least 18 years of age
-Have AML
-You have newly diagnosed AML

Age Range

18 - n/a

Healthy Volunteers Needed

No

Duration of Participation

You will receive the study drug for as long as you are tolerating it and your leukemia has not gotten worse. After you finish receiving the study drug, the investigator will continue to watch you for side effects and follow your condition 30 days after your last dose of study drug and then every 3 months for up to 2 years for survival.

Minors Included

No

Contact

Clinical Trials Information Line
Phone: 503-494-1080
Email: trials@ohsu.edu

Sponsor

Syros Pharmaceuticals, Inc.

Recruitment End

01/01/2026

Compensation Provided

No


Go Back